Japan approves rheumatoid drug Baricitinib for Covid-19 patients
Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December
FILE PHOTO: A woman wearing a protective face mask walks in a shopping district, amid the coronavirus disease (Covid-19) outbreak in Tokyo, Japan, July 2, 2020. REUTERS/Kim Kyung-Hoon
Japan's health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for Covid-19 patients, the third such approval following the drugs remdesivir and dexamethasone.
Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December.
Keep updated, follow The Business Standard's Google news channel
